Brinker Capital Investments’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.5M | Sell |
51,627
-2,186
| -4% | -$2.22M | 0.4% | 36 |
|
|
2025
Q4 | $57.8M | Buy |
53,813
+4,365
| +9% | +$4.17M | 0.42% | 38 |
|
|
2025
Q3 | $37.7M | Sell |
49,448
-1,375
| -3% | -$1.02M | 0.29% | 52 |
|
|
2025
Q2 | $39.6M | Buy |
50,823
+3,399
| +7% | +$2.64M | 0.34% | 46 |
|
|
2025
Q1 | $39.2M | Buy |
47,424
+3,855
| +9% | +$3.21M | 0.38% | 40 |
|
|
2024
Q4 | $33.6M | Buy |
43,569
+5,327
| +14% | +$4.41M | 0.34% | 48 |
|
|
2024
Q3 | $33.9M | Buy |
38,242
+816
| +2% | +$734K | 0.34% | 48 |
|
|
2024
Q2 | $33.9M | Buy |
37,426
+1,571
| +4% | +$1.26M | 0.36% | 48 |
|
|
2024
Q1 | $27.9M | Sell |
35,855
-930
| -3% | -$662K | 0.3% | 56 |
|
|
2023
Q4 | $23M | Sell |
36,785
-1,498
| -4% | -$874K | 0.27% | 73 |
|
|
2023
Q3 | $20.6M | Buy |
38,283
+5,170
| +16% | +$2.66M | 0.25% | 82 |
|
|
2023
Q2 | $15.5M | Sell |
33,113
-4,946
| -13% | -$2.07M | 0.17% | 122 |
|
|
2023
Q1 | $13.1M | Buy |
38,059
+9,921
| +35% | +$3.35M | 0.16% | 126 |
|
|
2022
Q4 | $10.3M | Buy |
28,138
+295
| +1% | +$105K | 0.2% | 107 |
|
|
2022
Q3 | $9M | Buy |
27,843
+1,198
| +4% | +$380K | 0.19% | 110 |
|
|
2022
Q2 | $8.64M | Sell |
26,645
-2,319
| -8% | -$696K | 0.16% | 129 |
|
|
2022
Q1 | $8.29M | Sell |
28,964
-435
| -1% | -$112K | 0.13% | 158 |
|
|
2021
Q4 | $8.12M | Buy |
29,399
+5,309
| +22% | +$1.35M | 0.12% | 168 |
|
|
2021
Q3 | $5.53M | Hold |
24,090
| – | – | 0.09% | 242 |
|
|
2021
Q2 | $5.53M | Buy |
24,090
+5,352
| +29% | +$1.08M | 0.07% | 287 |
|
|
2021
Q1 | $3.5M | Sell |
18,738
-20,345
| -52% | -$3.98M | 0.05% | 342 |
|
|
2020
Q4 | $6.6M | Buy |
39,083
+20,769
| +113% | +$3.1M | 0.1% | 240 |
|
|
2020
Q3 | $2.71M | Buy |
+18,314
| New | +$2.83M | 0.05% | 378 |
|
|
2020
Q1 | – | Sell |
-697
| Closed | -$92K | – | 556 |
|
|
2019
Q4 | $92K | Hold |
697
| – | – | ﹤0.01% | 372 |
|
|
2019
Q3 | $78K | Sell |
697
-15
| -2% | -$1.67K | ﹤0.01% | 392 |
|
|
2019
Q2 | $79K | Sell |
712
-92
| -11% | -$10.8K | ﹤0.01% | 527 |
|
|
2019
Q1 | $104K | Buy |
+804
| New | +$97.8K | ﹤0.01% | 387 |
|
|
2016
Q4 | – | Sell |
-40
| Closed | -$3K | – | 576 |
|
|
2016
Q3 | $3K | Buy |
+40
| New | +$3.2K | ﹤0.01% | 434 |
|
|
2016
Q1 | – | Sell |
-27
| Closed | -$2K | – | 573 |
|
|
2015
Q4 | $2K | Buy |
+27
| New | +$2.24K | ﹤0.01% | 465 |
|
Other funds holding LLY
VCM
VPM
Brinker Capital Investments's LLY Position: Q1 2026 in Review
Brinker Capital Investments reduced its Eli Lilly (LLY) stake by 4.1% in Q1 2026, selling an estimated $2.22M and leaving 51,627 shares worth $47.5M. The position accounts for 0.4% of the portfolio, ranked #36.
Brinker Capital Investments first reported a position in LLY in Q4 2015 and has held it in 29 quarters since. The position peaked at $57.8M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Brinker Capital Investments held 51,627 shares of Eli Lilly worth $47.5M as of Q1 2026.
- Brinker Capital Investments sold 2,186 Eli Lilly shares in Q1 2026, an estimated $2.22M.
- Eli Lilly made up 0.4% of Brinker Capital Investments's portfolio in Q1 2026, its #36 holding.
- Brinker Capital Investments first reported a position in Eli Lilly in Q4 2015 and has held it in 29 quarters since.
- Brinker Capital Investments's Eli Lilly position peaked at $57.8M in Q4 2025.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Brinker Capital Investments's 13F filing for Q1 2026, filed 13 May 2026.